Radiographic progression-free survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea J Pereira de Santana Gomes, Karina Vianna, Hong Luo, Geoffrey T Gotto, Heather H Cheng, Won Kim, Carly R Varela, Daneen Schaeffer, Kassie Kramer, Susan Li, Benoit Baron, Fei Shen, Suneel D Mundle, Sharon A McCarthy, David Olmos, Kim N Chi, Dana E Rathkopf
Nat Med 31(12) 4109-4118
Inhibition of poly(ADP-ribose) polymerase (PARP) after relapse on hormone therapy is well established for patients with prostate cancer with homologous recombination repair (HRR) gene alterations, but resistance often develops. We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve radiographic progression-free survival when added to standard-of-care treatments. The double-blind AMPLITUDE trial evaluated combining niraparib, a potent and specific PARP inhibitor, with abiraterone acetate and prednisone (AAP) versus placebo and AAP in mCSPC with HRR gene alterations. Patients (n = 696) were randomized in a 1:1 ratio (348 per group). Median age was 68 years; 56% had BRCA1 or BRCA2 alterations; 78% had high-volume metastases; and 16% had received docetaxel. The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed first in the BRCA subgroup (median not reached at the time of analysis for the niraparib and AAP group versus 26 months for the AAP group; hazard ratio = 0.52; 95% confidence interval: 0.37-0.72; P < 0.0001) and then in the intention-to-treat population (hazard ratio = 0.63; 95% confidence interval: 0.49-0.80; P = 0.0001). The data for overall survival, a key secondary endpoint, are immature (193/389 events) but favor niraparib (hazard ratio = 0.79 (95% confidence interval: 0.59-1.04); BRCA subgroup: hazard ratio = 0.75 (95% confidence interval: 0.51-1.11)). Incidence of grade 3 or 4 adverse events was 75% in the niraparib and AAP group and 59% in the AAP group; most frequent in the niraparib and AAP group were anemia (29%), with 25% of patients requiring a blood transfusion, and hypertension (27%). There were 14 treatment-emergent adverse events leading to deaths in the niraparib group and seven in the placebo group. Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring BRCA1/BRCA2 or other HRR gene alterations, suggesting clinical benefit with this combination for these patients. ClinicalTrials.gov identifier: NCT04497844 .
4 个 Figure · 12 个 KM 面板
Fig. 2. Radiographic progression-free survival. a − c , Kaplan−Meier estimates of investigator-assessed radiographic progression-free survival in the BRCA subgroup ( n = 387) ( a ), the HRR effector subgroup ( n = 456) ( b ) and the intention-to-treat population ( n = 696) ( c ). Radiographic progression-free survival was compared between treatment groups using the stratified log-rank test. Hazard ratios and 95% confidence intervals (CIs) were estimated by stratified Cox proportional hazards models. Forest plot of prespecified subgroup analysis in the intention-to-treat population; dots represent hazard ratio estimates, and whiskers represent 95% CIs ( d ). Vertical bars are censor marks. ADT, androgen deprivation therapy; BFI-SF, Brief Pain Inventory (Short Form); NE, not estimable; PS, performance status.
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel C
Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3. Secondary endpoints. a − d , Kaplan−Meier estimates of time to symptomatic progression ( a , b ) and overall survival ( c , d ) in the BRCA subgroup ( n = 387) ( a , c ) and the intention-to-treat population ( n = 696) ( b , d ) ordered as per the sequence for efficacy testing conducted in the hierarchical graphical approach. Comparisons between treatment groups used the stratified log-rank test. Hazard ratios and 95% confidence intervals were estimated by stratified Cox proportional hazards models. To be concise, Kaplan−Meier estimates in the HRR effector subgroup are in Extended Data Fig. 2. Vertical bars are censor marks.
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C
Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D
Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 1. Kaplan-Meier estimates of radiographic progression-free survival in the (a) BRCA subgroup (n = 387), (b) HRR effector subgroup (n = 456) and (c) intention-to-treat population (n = 696) by blinded independent central review. Radiographic progression-free survival was compared between treatment groups using the stratified log-rank test. HRs and 95% CIs were estimated by stratified Cox proportional-hazards models. Vertical bars are censor marks. NE, not estimable.
Extended Data Fig. 1 · Panel A
Panel A 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 1 · Panel B
Panel B 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 1 · Panel C
Panel C 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 2. Kaplan-Meier estimates of time to symptomatic progression (a) and overall survival (b) in the HRR effector subgroup (n = 456). Comparison between treatment groups was performed using the stratified log-rank test. HRs and 95% CIs were estimated by stratified Cox proportional-hazards models. Vertical bars are censor marks.
Extended Data Fig. 2 · Panel A
Panel A 是同一 Extended Data Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 2 · Panel B
Panel B 是同一 Extended Data Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。